Aethlon Medical's Cancer Therapy Receives "Breakthrough Device" Designation from the U.S. Food and Drug Administration

Stock Information for Aethlon Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aethlon Medical Inc.

Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer
Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023
Aethlon Receives Clearance From Drug Controller General of India For Potential Phase 1 Trial of its Hemopurifier® in Oncology
Aethlon Announces Reverse Stock Split

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.